290 related articles for article (PubMed ID: 24048821)
1. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.
Perret R; Sierro SR; Botelho NK; Corgnac S; Donda A; Romero P
Cancer Res; 2013 Nov; 73(22):6597-608. PubMed ID: 24048821
[TBL] [Abstract][Full Text] [Related]
2. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
Gritzapis AD; Voutsas IF; Baxevanis CN
Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
[TBL] [Abstract][Full Text] [Related]
3. Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells.
Sun JB; Czerkinsky C; Holmgren J
Scand J Immunol; 2007; 66(2-3):278-86. PubMed ID: 17635805
[TBL] [Abstract][Full Text] [Related]
4. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
5. Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cells.
Wang J; Su B; Ding Z; Du X; Wang B
Biochem Biophys Res Commun; 2008 Aug; 372(3):491-6. PubMed ID: 18502198
[TBL] [Abstract][Full Text] [Related]
6. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
[TBL] [Abstract][Full Text] [Related]
7. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
8. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
Saha A; Baral RN; Chatterjee SK; Mohanty K; Pal S; Foon KA; Primus FJ; Krieg AM; Weiner GJ; Bhattacharya-Chatterjee M
Cancer Immunol Immunother; 2006 May; 55(5):515-27. PubMed ID: 16044253
[TBL] [Abstract][Full Text] [Related]
9. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
10. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
Zhou G; Ding ZC; Fu J; Levitsky HI
J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.
Yan X; Zhang X; Wang Y; Li X; Wang S; Zhao B; Li Y; Ju Y; Chen L; Liu W; Meng S
Cancer Immunol Immunother; 2011 Dec; 60(12):1763-74. PubMed ID: 21789592
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant.
Hitzler I; Oertli M; Becher B; Agger EM; Müller A
Gastroenterology; 2011 Jul; 141(1):186-96, 196.e1. PubMed ID: 21569773
[TBL] [Abstract][Full Text] [Related]
13. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
14. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
15. Concurrent allorecognition has a limited impact on posttransplant vaccination.
Manzo T; Hess Michelini R; Basso V; Ricupito A; Chai JG; Simpson E; Bellone M; Mondino A
J Immunol; 2011 Feb; 186(3):1361-8. PubMed ID: 21209285
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
Rech AJ; Vonderheide RH
Ann N Y Acad Sci; 2009 Sep; 1174():99-106. PubMed ID: 19769742
[TBL] [Abstract][Full Text] [Related]
18. The adjuvant effect of TLR agonists on CD4(+) effector T cells is under the indirect control of regulatory T cells.
Olivier A; Sainz-Perez A; Dong H; Sparwasser T; Majlessi L; Leclerc C
Eur J Immunol; 2011 Aug; 41(8):2303-13. PubMed ID: 21538349
[TBL] [Abstract][Full Text] [Related]
19. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.
Teramoto K; Kontani K; Fujita T; Ozaki Y; Sawai S; Tezuka N; Fujino S; Itoh Y; Taguchi O; Kannagi R; Ogasawara K
Cancer Immunol Immunother; 2007 Mar; 56(3):331-42. PubMed ID: 16896967
[TBL] [Abstract][Full Text] [Related]
20. Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice.
Tanaka K; Ishikawa S; Matsui Y; Kawanishi T; Tamesada M; Harashima N; Harada M
Cancer Immunol Immunother; 2012 Nov; 61(11):2143-52. PubMed ID: 22588648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
